Back to Results

ISpecimen Inc (ISPC)

iSpecimen Inc. is a healthcare technology company listed on NASDAQ as common stock under the ticker ISPC. The company operates iSpecimen Marketplace, an online platform designed to connect life science researchers with hospitals, laboratories, and other organizations that can provide access to human biospecimens, related subjects, and data. Its marketplace includes a range of specimen types, such as biofluids, solid tissue, and hematopoietic stem and immune cells. These offerings support customers including biopharmaceutical companies, in vitro diagnostic companies, and government and academic institutions. Incorporated in 2009, iSpecimen Inc. is headquartered in Woburn, Massachusetts.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ISPC
$1.58
26.7% Upside
Undervalued
Not available
Not available
Weak
0.0%
November 13, 2026
1.9x
7.1x
3.148 M
-848.923 K
6.8%
100.0%
-70.0
61.3%
Valuation • Fair Value

iSpecimen Inc (NASDAQ-ISPC) Fair Value by Valuation Model

Review the available estimates for iSpecimen Inc (NASDAQ-ISPC), including EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$1.58

Estimated upside of 26.7% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

EPV Fair Value

$2.14

Earnings power value estimate.

Comps Fair Value

$1.47

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for iSpecimen Inc (NASDAQ-ISPC) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for iSpecimen Inc (NASDAQ-ISPC)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

466.302 K

Current operating scale indicator.

Revenue Forecast

14.238 M

Forward revenue estimate.

EBITDA

-9.285 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review iSpecimen Inc (NASDAQ-ISPC) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for iSpecimen Inc (NASDAQ-ISPC)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-8.50

No elevated caution signal from this screen.

Altman Z-Score

-70.0

Lower score that deserves closer risk review.

FCF / Net Income

61.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for iSpecimen Inc (NASDAQ-ISPC). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for iSpecimen Inc (NASDAQ-ISPC)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

52

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for iSpecimen Inc (NASDAQ-ISPC), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

iSpecimen Inc (NASDAQ-ISPC) Stock Forecast & Technical Outlook

Review iSpecimen Inc (NASDAQ-ISPC) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for iSpecimen Inc (NASDAQ-ISPC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for iSpecimen Inc (NASDAQ-ISPC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for iSpecimen Inc (NASDAQ-ISPC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for iSpecimen Inc (NASDAQ-ISPC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for iSpecimen Inc (NASDAQ-ISPC) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for iSpecimen Inc (NASDAQ-ISPC)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, iSpecimen Inc (NASDAQ-ISPC) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

iSpecimen Inc (NASDAQ-ISPC) Stock FAQ

Data-supported answers about iSpecimen Inc (NASDAQ-ISPC), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.58
Estimated upside 26.7%
Valuation Rating
Undervalued
Estimated upside of 26.7%
Financial Health
Weak
Current financial-health read

The current fair value estimate for iSpecimen Inc (NASDAQ-ISPC) is $1.58. This implies an estimated upside of 26.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 26.7% versus the current market price.

The current financial health read for iSpecimen Inc (NASDAQ-ISPC) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for iSpecimen Inc (NASDAQ-ISPC) is November 13, 2026.

The latest available data indicates no current dividend yield for iSpecimen Inc (NASDAQ-ISPC).

The current market capitalization listed for iSpecimen Inc is 3.148 M.

The current enterprise value listed for iSpecimen Inc is -848.923 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for iSpecimen Inc is NASDAQ-ISPC, and the stock is listed on NASDAQ.

iSpecimen Inc (NASDAQ-ISPC) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for iSpecimen Inc is 6.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for iSpecimen Inc is 100.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Health Care Technology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

VEEV NYSE Veeva Systems Inc Class A Fair Value Fair Market Cap 42.244 B
WAY NASDAQ Waystar Holding Corp Fair Value Undervalued Market Cap 4.915 B
DOCS NYSE Doximity Inc Fair Value Undervalued Market Cap 4.725 B
HTFL NASDAQ Heartflow Inc Fair Value Overvalued Market Cap 4.362 B
SDGR NASDAQ Schrodinger Inc Fair Value Overvalued Market Cap 2.297 B
CERT NASDAQ Certara Inc Fair Value Undervalued Market Cap 1.347 B
GDRX NASDAQ Goodrx Holdings Inc Fair Value Undervalued Market Cap 1.174 B
TDOC NYSE Teladoc Inc Fair Value Undervalued Market Cap 1.154 B
HSTM NASDAQ HealthStream Inc Fair Value Fair Market Cap 887.6 M
SOPH NASDAQ Sophia Genetics SA Fair Value Overvalued Market Cap 687 M
PHR NYSE Phreesia Inc Fair Value Undervalued Market Cap 626.9 M
CTEV NYSE Claritev Corp Fair Value Overvalued Market Cap 499.1 M
EVH NYSE Evolent Health Inc Fair Value Fair Market Cap 429.6 M
SLP NASDAQ Simulations Plus Inc Fair Value Undervalued Market Cap 372.3 M
AMWL NYSE American Well Corp Fair Value Undervalued Market Cap 224.7 M
LFMD NASDAQ LifeMD Inc Fair Value Undervalued Market Cap 159.1 M
OPRX NASDAQ OPTIMIZERx Corp Fair Value Bargain Market Cap 143.5 M
HCAT NASDAQ Health Catalyst Inc Fair Value Fair Market Cap 142.2 M
DH NASDAQ Definitive Healthcare Corp Fair Value Bargain Market Cap 129.3 M
CCLD NASDAQ CareCloud Inc Fair Value Fair Market Cap 91.362 M